BamSEC and AlphaSense Join Forces
Learn More

VYNE Therapeutics Inc. – Plans of Reorganization, Merger, Acquisition or Similar

NASDAQ: VYNE    
Share price (5/28/26): $0.69    
Market cap (5/28/26): $22.9 million
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 115 pages Agreement and Plan of Merger and Reorganization Among: VYNE Therapeutics Inc.; Yellow Merger Sub Corp.; and Yarrow Bioscience, Inc. Dated as of December 17, 2025
12/34/56
EX-2.1
from 425 115 pages Agreement and Plan of Merger and Reorganization Among: VYNE Therapeutics Inc.; Yellow Merger Sub Corp.; and Yarrow Bioscience, Inc. Dated as of December 17, 2025
12/34/56
EX-2.1
from 8-K 52 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Both (I) Is Not Material and (II) Is the Type of Information That the Registrant Customarily and Actually Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[***].” Asset Purchase Agreement Between VYNE Therapeutics Inc. and Journey Medical Corporation Dated as of January 12, 2022
12/34/56
EX-2.1
from 8-K 3 pages Amendment No. 1 to the Agreement and Plan of Merger
12/34/56
EX-2.1
from 425 3 pages Amendment No. 1 to the Agreement and Plan of Merger
12/34/56
EX-2.2
from S-4 3 pages Amendment No. 1 to the Agreement and Plan of Merger
12/34/56
EX-2.1
from 8-K 115 pages Agreement and Plan of Merger by and Among Menlo Therapeutics Inc. Giants Merger Subsidiary Ltd. and Foamix Pharmaceuticals Ltd. Dated as of November 10, 2019
12/34/56
EX-2.1
from 425 115 pages Agreement and Plan of Merger by and Among Menlo Therapeutics Inc. Giants Merger Subsidiary Ltd. and Foamix Pharmaceuticals Ltd. Dated as of November 10, 2019
12/34/56
EX-2.1
from 425 124 pages Agreement and Plan of Merger by and Among Menlo Therapeutics Inc. Giants Merger Subsidiary Ltd. and Foamix Pharmaceuticals Ltd. Dated as of November 10, 2019
12/34/56